A biopharmaceutical company, which focused on developing and commercializing novel pain management therapies.
The best Bull and Bear pitches based on recency and number of recommendations.
Let's see, how am I going to defend this impulsive green thumb? NeurogesX is garbage, but the last nail isn't in the coffin yet. Having failed to interest physicians and patients in a capsaicin patch, the company is now progressing the development of… More
I held off red-thumbing NeurogesX before the recent Ad Comm meeting even though it seemed pretty clear that the panel would vote against approval. The reason for that, of course, is that CAPS rewards players who luck into the bottom of a stock but… More
Read the most recent pitches from players about NGSX.
Find the members with the highest scoring picks in NGSX.
anticitrademix (< 20) Score: +502.12
The Score Leader is the player with the highest score across all their picks in NGSX.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
anticitrademix2 | < 20 | 11/2/2009 | 5Y | $7.94 | -99.80% | +402.32% | +502.12 | 0 Comment | ||
anticitrademix | < 20 | 11/2/2009 | 5Y | $7.94 | -99.80% | +402.32% | +502.12 | 0 Comment | ||
MicroCaptain | < 20 | 1/29/2010 | 1Y | $7.12 | -99.78% | +377.35% | +477.12 | 0 Comment | ||
longtermgrowth09 | 67.47 | 12/17/2009 | 5Y | $7.43 | -99.78% | +372.43% | +472.21 | 0 Comment | ||
Cannabis911 | 98.15 | 12/11/2009 | 5Y | $7.78 | -99.79% | +370.77% | +470.56 | 0 Comment | ||
39272x3 | 31.07 | 11/18/2009 | 5Y | $8.98 | -99.82% | +370.13% | +469.95 | 0 Comment | ||
TarpWatchdog | 98.69 | 12/14/2009 | 5Y | $7.80 | -99.79% | +367.57% | +467.36 | 0 Comment | ||
shorttest4 | 53.09 | 3/8/2010 | 5Y | $7.94 | -99.80% | +357.79% | +457.59 | 0 Comment | ||
anticishort | 33.12 | 3/30/2010 | 5Y | $9.65 | -99.83% | +345.32% | +445.15 | 0 Comment | ||
MaxPwr273 | 69.30 | 10/26/2011 | 5Y | $1.07 | -98.50% | +319.63% | +418.14 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.